Document |
Document Title |
WO/2015/169769A1 |
A method of enhancing the sweetness of sweetener in a food or beverage product comprising adding Naringenin to the product in an amount of 50 ppm to 200 ppm by weight of the total weight of the product wherein the Naringenin does not blo...
|
WO/2015/166041A1 |
The present application relates to a compound of formula (I) for use in the prevention and/or treatment of cancer, wherein R1 to R9 are independently selected from hydrogen, aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cya...
|
WO/2015/162538A1 |
The invention relates to heterocyclic compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their pharmaceutical compositions for use in medicine for the treatment of ...
|
WO/2015/160307A1 |
There is provided a compound of formula I, having the structure: wherein R1 to R5 have the meanings given in the description.
|
WO/2015/160321A1 |
The present invention is about 8 different molecules, created from Chromene-2-one, their derivatives and pharmaceutical compositions containing these compounds. In generated 8 different molecule Rl and R2 positions were chosen as site of...
|
WO/2015/161309A1 |
Certain embodiments are directed to apigenin analogues or derivatives. In certain aspects, the derivatives are developed as cystathionine-beta-synthase (CBS) inhibitors. In certain aspects, the derivatives are used as anticancer or anti-...
|
WO/2015/153813A1 |
The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the sa...
|
WO/2015/153648A1 |
This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of us...
|
WO/2015/144911A1 |
This invention relates to 3-phenyl-7-hydroxy-isocoumarin compounds which are MIF inhibitors, compositions comprising said inhibitors and methods for treating or preventing diseases associated with MIF.
|
WO/2015/145371A1 |
The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparati...
|
WO/2015/141775A1 |
The purpose of the present invention is to provide an agent for the prevention or treatment of inflammatory disease or degenerative disc disease. A coumarin derivative or a pharmaceutically acceptable salt or hydrate thereof that is the ...
|
WO/2015/135061A1 |
Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA ...
|
WO/2015/134610A1 |
The present invention provides methods for treating or preventing diabetic nephropathy and its related pathologies by inhibiting podocyte Semaphorin3a (Sema3a). The invention also provides a method for identifying or characterizing a com...
|
WO/2015/134357A1 |
This disclosure relates to methods and pharmaceutical compositions for the treatment and prevention of diabetes. In certain embodiments, compounds disclosed herein are 2Η,2Ή- [9,9'-bibenzo[g]chromene]-4,4'(3H,3'H)-dione and its derivat...
|
WO/2015/129813A1 |
The present invention provides: a deuteration method that is both cost effective and has an excellent deuteration rate; a method for selectively replacing a leaving group of an aromatic compound with deuterium; and a deuteration catalyst...
|
WO/2015/127118A1 |
This invention describes a simple, rapid and cost-effective method to isolate bulk quantities of relatively pure and enriched anthocyanidins and other plant bioactives. The method is based on the principle of solubility. Some bioactives ...
|
WO/2015/124114A1 |
Disclosed are a phenolic hydroxyl flavone compound semisynthesis method and iodine recovery method, relating to approaches A and B and iodine recovery. In approach A, flavone is dissolved in a pyridine solvent of ethylene glycol or glyce...
|
WO/2015/123783A1 |
Compounds that are cathepsin B substrates and that are useful as imaging probes, for example in positron emission tomography (PET) or fluorescence imaging are described.
|
WO/2015/124113A1 |
Provided is a semi-synthesis method for luteolin, galuteolin and luteolin rutinoside. In the method, two steps of dehydrogenation and demethylation are combined into one step, and reaction conditions of dehydrogenation and demethylation ...
|
WO/2015/125892A1 |
The present invention provides a compound that is represented by general formula (I) (In the formula, Z represents AA. Y 1 represents N or CR1, Y2 represents N or CR2, Y3 represents N or CR3, and Y4 represents N or CR4. One of R1-R4 in...
|
WO/2015/121452A1 |
The invention relates to a process for producing Nebivolol hydrochloride, (formula I) comprising the steps of: provision of a protected Nebivolol hydrochloride of the general formula (II), with P being an amine protecting group, and hydr...
|
WO/2015/117202A1 |
The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence ...
|
WO/2015/119436A1 |
The present specification relates to a fullerene derivative, an organic solar cell using the same, and a preparation method therefor.
|
WO/2015/116460A1 |
A family of compounds which function as selective ligands for the serotonin receptor 2B (5-HT2B) is identified. Some of the compounds are synthetic non-natural ligands which have a relatively strong interaction with 5-HT2B compared to na...
|
WO/2015/112898A1 |
Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.
|
WO/2015/109013A1 |
The present invention provides deuterated NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein Z, R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical comp...
|
WO/2015/109014A1 |
The present invention provides NO-releasing NONOate(oxygen bound)chromene conjugates, having the structure of Formula (I): wherein Z, R1, R2, R3, R4, R5, R6, and R7 are as defined in the detailed description; pharmaceutical compositions ...
|
WO/2015/109011A1 |
The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1 ) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comp...
|
WO/2015/101339A1 |
Provided is a compound represented by formula I, wherein R9 is a C1-C22 hydrocarbyl group or a C2-C3 ester-substituted C1-C3 alkyl group, R5, R6, R7 and R8 are alkyl groups or H, and R1, R2, R3 and R4 are H or lower hydrocarbyl groups. O...
|
WO/2015/100506A1 |
The invention relates to a method for producing a concentrated extract comprising phenolic compounds and having a high antioxidant activity from fruit obtained from apple thinning, said method comprising: freezing the fruit resulting fro...
|
WO/2015/096347A1 |
The present disclosure relates to a leveling composition for electrodepositing metals. The composition comprises a compound of formula (I).
|
WO/2015/097461A1 |
A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range o...
|
WO/2015/097463A1 |
The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain i...
|
WO/2015/098681A1 |
The problem of providing a cockroach-aggregating pheromone and a cockroach-aggregating attractant or a cockroach exterminating agent which includes the cockroach-aggregating pheromone is solved by a compound represented by any of general...
|
WO/2015/100213A2 |
Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs ...
|
WO/2015/091943A1 |
The present invention relates to a method for manufacturing enantiomerically pure (13R)-manoyl oxide, said method comprising the steps of contacting geranylgeranyl diphosphate (GGPP) with a class II diterpene synthase to obtain labd-13-e...
|
WO/2015/094688A1 |
A method for preparation of an acidic stabilized syrup concentrate containing rebaudioside B and a stabilizer additive. Acidic stabilized syrup concentrate compositions are also provided.
|
WO/2015/085459A1 |
The present invention relates to a compound for inhibiting the activity of Glutathione s-transferase omega 1 and pharmaceutical compositions thereof. The present invention also relates to a method for preparing the above-mentioned compou...
|
WO/2015/083663A1 |
A purpose of the present invention is to provide a polymerizable monomer having low contamination with respect to liquid crystals, high sensitivity to light of long wavelengths, and an exceptional sensitizing effect, and a polymer compou...
|
WO/2015/080240A1 |
The purification method according to the present invention is for either a compound expressed by formula (1) or a resin having the structure exhibited by formula (2), and contains a step in which an acidic water-soluble solution is conta...
|
WO/2015/077141A1 |
The present invention relates to intermediate compounds represented by the following Formula (l-A), The intermediate compounds of the present invention, such as represented by Formula (I-A), can be used to prepare photochromic compounds,...
|
WO/2015/077264A1 |
The present invention relates to photochromic indeno-fused ring pyran compounds represented by the following Formula (I-A): The present invention also relates to photochromic dichroic compounds, such as represented by Formula (I-A), in w...
|
WO/2015/071665A1 |
A fluorogenic compound comprising a biologically active component and a hypoxia- activated protecting group which is fluorogenic. The biologically active component is bound to the fluorogenic component at an active binding position such ...
|
WO/2015/073527A1 |
Within the scope of the present invention is a new pharmacological strategy for the treatment of atherosclerosis based on the main pathogenic role that low density lipoproteins and chronic inflammation play in atherogenesis. This pharmac...
|
WO/2015/067833A1 |
The invention relates to coumarins of formula (I), to polyols and polyurethanes comprising said coumarin, and to the method for producing said polyurethanes, the use thereof in the preparation of coating films, and the method thereof for...
|
WO/2015/063798A1 |
The present invention discloses one-pot synthesis of various carboxylic acid derivatives using copper catalyst and sodium cyanide as the cyanide source for bringing in carbonylative coupling in a single step.
|
WO/2015/061518A1 |
Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula :(I)
|
WO/2015/061397A1 |
Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the gene...
|
WO/2015/059129A1 |
The present invention relates to the preparation of chromane compounds and their derivatives by a copper-catalyzed conjugate addition reaction. It has been observed that in highly stereoselective manner a methyl group can be introduced t...
|
WO/2014/123102A9 |
This material for forming an underlayer film for lithography contains a compound represented by general formula (I). (In formula (I): X each independently is an oxygen atom or a sulfur atom; R1 is a single bond or a 2n-valent hydrocarbon...
|